Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients for their clinical trial.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Sen-Jam Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Sen-Jam Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Sen-Jam Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 22, 2022